Advance Best-In-Class Treatment Across CNS, Emergency Use Treatments, & Infectious Diseases & Secure Long-Term Funding in Intranasal Delivery
1-3 April, 2025 | Boston, MA
Welcome to the 3rd Nasal Formulation & Delivery Summit
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use, nasal delivery is opening a new era of more efficient drug and vaccine administration with life-saving potential. However, challenges in biologics formulation, along with renewed interest from major pharmaceutical companies and investors, raise questions about how other companies are addressing development obstacles and the most effective strategies to secure funding.
Dedicated to navigating investment pathways for nasal companies, boosting drug bioavailability in target regions, optimizing translational modelling, and determining the efficacy of delivery devices, the 3rd Nasal Formulation & Delivery Summit will unite biotechs and innovative start-ups to share case studies and best practices in optimizing nasal drug delivery across different therapeutic areas. We will be shining the spotlight on:
Meet Your Expert Speaker Faculty:
Testimonials From Past Participants Across our Nasal Series:
“Lots of novel ideas! A good atmosphere to exchange ideas and as well network with people in the field of intranasal delivery” - Altpep Corporation
“Unique conference topic, not many conferences that bring together experts focused on this niche space” - Aptar
“Well organized conference on a specialized topic that is becoming an important route of administration. Gathering experts in this area made for a very dynamic and informative conference” - Cybin Inc
“A good blend of industry, academia, CDMOs and device providers which provides for a good environment to learn about this type of application” - Maxwell Biosciences
“This event is dedicated to innovation in the field of nasal delivery. The quality of the speakers and the audience provides rich source of information and interesting discussions” - Nemera
Our 2025 Partners:
